Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
New Formulation of F18 (NDA), March 6 Lantheus Holdings For a new formulation of F18 PSMA-targeted PET imaging agent to determine the presence or absence of recurrent and/or metastatic prostate cancer
3A, B, S4A, B, and Supplementary Data S3)
Because the two receptors sit on different pathways, a combination has a mechanistic rationale
Membership: $79/month, with a $39 first-month promo available at the time of this July 2026 update
This, in turn, upregulates GPX4 and other genes to prevent fatal seizures [29]
US$ 26.43
US$ 25.64
US$ 22.69
US$ 29.87
US$ 28.89
US$ 29.85
